Altoida

Altoida operates at the intersection of digital biomarkers, cognitive diagnostics, augmented reality, and medical-device software. Its differentiation is the combination of a roughly 10-minute, self-administered assessment with motor, speech, cognitive, and AR-derived signals, rather than relying only on questionnaire-based screening or clinic-bound testing. The company says its platform is designed for screening, clinical-trial enrichment, treatment monitoring, and disease-progression research, giving it potential relevance to providers, pharmaceutical companies, and researchers. Its Class II, 510(k)-exempt computerized cognitive assessment aid and July 2021 FDA Breakthrough Device Designation provide more regulatory specificity than a general wellness application. Altoida has also reported a research base spanning more than 20 years, nearly 20,000 participants, and tens of thousands of assessments. The $24.75 million funding total and 15-investor base indicate meaningful specialist backing, but the company remains private and relatively small.

Altoida’s trajectory reflects a long product-development cycle followed by increasing clinical and partnership activity. The company’s funding history begins with two Venture Kick grants in 2014, followed by a 2016 seed round, a 2018 convertible note, and a $6.3 million Series A in 2019. It added a $2 million convertible note in 2020, a $498,335 round in 2021, and a $14 million Series A announced on Mar 30, 2022, bringing recorded funding to $24.75 million across nine rounds. The July 2021 FDA Breakthrough Device Designation marked a regulatory inflection point, while the 2022 Chief Medical Officer appointment and 2023 CEO transition indicate efforts to strengthen clinical and regulatory execution. In 2026, collaborations with Mindspan and Circular Genomics expanded the platform into personalized cognitive care and multimodal Alzheimer’s precision medicine. Altoida also maintained an active careers page in September 2025 and reports an employee range of 11–50, suggesting ongoing but measured team development.